Pancreatic Cancer Research

ResearcherHarbin Medical UniversityNo recent work listed

Zhongjie Zhao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0213-0426; OpenAlex author ID A5036911242. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
30
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 4 papers

Papers 9

  1. Tumor Cell Derived Lnc-FSD2-31:1 Contributes to Cancer-Associated Fibroblasts Activation in Pancreatic Ductal Adenocarcinoma Progression through Extracellular … Co-author DOI 10.1002/advs.202203324↗
  2. DUSP2 recruits CSNK2A1 to suppress AKT1-mediated apoptosis resistance under hypoxic microenvironment in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216288↗
  3. circEIF3I facilitates the recruitment of SMAD3 to early endosomes to promote TGF-β signalling pathway-mediated activation of MMPs in pancreatic cancer. Co-author DOI 10.1186/s12943-023-01847-2↗
  4. The Prognostic and Immune Significance of CILP2 in Pan-Cancer and Its Relationship with the Progression of Pancreatic Cancer. Co-author DOI 10.3390/cancers15245842↗
  5. Positive feedback regulation of lncRNA TPT1-AS1 and ITGB3 promotes cell growth and metastasis in pancreatic cancer. Co-author DOI 10.1111/cas.15388↗
  6. Cancer-Associated Fibroblast (CAF) Heterogeneity and Targeting Therapy of CAFs in Pancreatic Cancer. Co-author DOI 10.3389/fcell.2021.655152↗
  7. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1. Co-author DOI 10.1186/s13046-019-1278-9↗
  8. Overexpression of KLF5 is associated with poor survival and G1/S progression in pancreatic cancer. Co-author DOI 10.18632/aging.102096↗
  9. Plasma and tumor levels of Linc-pint are diagnostic and prognostic biomarkers for pancreatic cancer. Co-author DOI 10.18632/oncotarget.12365↗

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hongze Chen · 7 shared papers, 2016–2023 · strength 0.76
  2. Danxi Liu · 5 shared papers, 2022–2023 · strength 0.74
  3. Jisheng Hu · 6 shared papers, 2019–2023 · strength 0.70
  4. Chundong Cheng · 5 shared papers, 2019–2023 · strength 0.62
  5. Yongwei Wang · 5 shared papers, 2016–2023 · strength 0.60
  6. Xinglong Geng · 4 shared papers, 2021–2023 · strength 0.56
  7. Wenbo Yang · 4 shared papers, 2021–2023 · strength 0.56
  8. Rui Kong · 5 shared papers, 2016–2023 · strength 0.56
  9. Bei Sun · 5 shared papers, 2016–2023 · strength 0.53
  10. Le Li · 4 shared papers, 2019–2023 · strength 0.49
  11. Yangyang Zhang · 3 shared papers, 2023 · strength 0.44
  12. Guanqun Li · 3 shared papers, 2021–2023 · strength 0.41
  13. Bei Sun · 3 shared papers, 2021–2023 · strength 0.41
  14. Shangha Pan · 4 shared papers, 2016–2023 · strength 0.41
  15. Zonglin Liu · 2 shared papers, 2022–2023 · strength 0.30
  16. Yan Luo · 2 shared papers, 2023 · strength 0.30
  17. Yilong Li · 3 shared papers, 2019–2022 · strength 0.30
  18. Gang Wang · 3 shared papers, 2016–2023 · strength 0.28
  19. Tao Zhang · 2 shared papers, 2022–2023 · strength 0.27
  20. Le Li · 2 shared papers, 2019–2021 · strength 0.21
  21. Le Li · 2 shared papers, 2016–2023 · strength 0.21
  22. Liwei Liu · 1 shared paper, 2023 · strength 0.15
  23. Hongze Chen · 1 shared paper, 2023 · strength 0.15
  24. Bei Sun · 1 shared paper, 2023 · strength 0.15
  25. Zengfu Song · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.